Clever gene construct combats metabolic syndrome

December 18, 2012 by Peter Rüegg
Tastes nice but is unhealthy: anyone who makes a habit of eating fast food and does not do enough exercise can expect various symptoms of metabolic syndrome, such as high blood pressure, obesity and diabetes. Credit: SteFou!/Flickr

(Medical Xpress)—Researchers under ETH-Zurich professor Martin Fussenegger have created a new genetic network that could cure the various symptoms of so-called metabolic syndrome in one fell swoop. It already works in mice.

Too much of the wrong food and not enough exercise: sooner or later, an increasing number of people in industrial nations pay the price for their lifestyle. High , changed blood fat values, as a precursor to diabetes, and abdominal fat are characteristic of metabolic syndrome, the 'killer of the twenty-first century'. After all, it is the major risk factor for the development of coronary heart diseases. Today, many more people die of cardiovascular diseases worldwide than from cancer.

Until now, however, there has not been a holistic therapy for metabolic syndrome. Medicine diagnoses and treats every single symptom of metabolic syndrome separately. "However, all these diseases are linked," says ETH-Zurich professor Martin Fussenegger from the Department of Biosystems in Basel. His research group has now found an approach that could treat all the symptoms of metabolic syndrome at once.

Antihypertensive drug triggers cascade

The biotechnologists have constructed a synthetic signaling cascade from different that can be triggered with the antihypertensive drug guanabenz and controlled based on the dosage. After the start signal, a is set in motion in the cell and culminates with the production of a "super hormone" in the . This includes GLP1, which is connected to leptin via a molecular bridge. GLP1 reduces the ; leptin inhibits the feeling of hunger and thus plays a key role in regulating the .

The combination of the drug guanabenz, which has already been approved for clinical use, and the 'super hormone' produced by the synthetic signal cures all three key diseases associated with metabolic syndrome at the same time.

The researchers tested their network in a model experiment using diabetic, obese mice suffering from . The animals lack the satiety hormone leptin so are always hungry and eat more than is good for them. The ETH-Zurich biotechnologists inserted an implant with ten million cells, each of which contained the synthetic signalling pathway, into the mice.

Construct successful in mice

The animals responded very well to the dose of guanabenz: the GLP1 and leptin concentration rose dramatically and twenty-four hours after the drug was dispensed insulin secretion also increased on account of the GLP1 content. After only three days, the level of cholesterol and other free fatty acids in the blood dropped – a good sign that the animals were beginning to recover from metabolic syndrome. Free guanabenz even lowered the blood pressure, too.

"This application is also realistic for the treatment of metabolic syndrome in humans," Fussenegger predicts. GLP1 is already administered as an alternative to insulin in the battle against diabetes. Leptin, on the other hand, would have to be substituted with another hormone that has a similar effect. "Leptin has failed to live up to its hopes as a therapeutic agent against obesity, as obese patients have sufficient leptin but have grown resistant to it," stresses the ETH-Zurich professor. However, he is confident that they can incorporate an alternative satiety hormone into their network. They merely used leptin to demonstrate the principle. It works perfectly well in mice.

In planning and constructing this network, the researchers were able to fall back on the Fussenegger group's existing expertise. The ingenious scientists had already assembled gene networks for diabetes or gout with similar biological components, the properties of which are renowned. "But we only discovered that the antihypertensive drug guanabenz can be used as a start button by chance," says the ETH-Zurich professor from Basel.

Even though he is convinced that a gene construct designed in this way could treat with its array of symptoms, for the time being Fussenegger is reluctant to make any promises as to when a corresponding product might hit the market.

Explore further: Metabolic syndrome makes a difference in hormone therapy risk

More information: Ye H, Charpin-El Hamri G, Zwicky K, Christen M, Folcher M, Fussenegger M. Pharmaceutically controlled designer circuit for the treatment of the metabolic syndrome. PNAS online, doi: 10.1073/pnas.1216801110

Related Stories

Metabolic syndrome makes a difference in hormone therapy risk

October 30, 2012

A new analysis of the Women's Health Initiative (WHI) trials show that women who had metabolic syndrome before they started hormone therapy had a greatly increased risk of heart attack or dying of heart disease. Women who ...

Recommended for you

We've all got a blind spot, but it can be shrunk

August 31, 2015

You've probably never noticed, but the human eye includes an unavoidable blind spot. That's because the optic nerve that sends visual signals to the brain must pass through the retina, which creates a hole in that light-sensitive ...

Biologists identify mechanisms of embryonic wound repair

August 31, 2015

It's like something out of a science-fiction movie - time-lapse photography showing how wounds in embryos of fruit flies heal themselves. The images are not only real; they shed light on ways to improve wound recovery in ...

New 'Tissue Velcro' could help repair damaged hearts

August 28, 2015

Engineers at the University of Toronto just made assembling functional heart tissue as easy as fastening your shoes. The team has created a biocompatible scaffold that allows sheets of beating heart cells to snap together ...

Fertilization discovery: Do sperm wield tiny harpoons?

August 26, 2015

Could the sperm harpoon the egg to facilitate fertilization? That's the intriguing possibility raised by the University of Virginia School of Medicine's discovery that a protein within the head of the sperm forms spiky filaments, ...

Research identifies protein that regulates body clock

August 26, 2015

New research into circadian rhythms by researchers at the University of Toronto Mississauga shows that the GRK2 protein plays a major role in regulating the body's internal clock and points the way to remedies for jet lag ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

JVK
1 / 5 (1) Dec 18, 2012
Do the epigenetic effects of the drug take into account any of the 4.5 million other DNA switches that might be altered via the same pathway? For example, could side effects be controlled with another drug like the one that's being developed for depression, which reportedly has no ketamine-like side effects? "GLYX-13, an NMDA Receptor Glycine-Site Functional Partial Agonist, Induces Antidepressant-Like Effects Without Ketamine-Like Side Effects'

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.